Abstract: An internal combustion engine includes a first blow-by gas passage defined in a second wall. The internal combustion engine includes a second blow-by gas passage defined in a third wall. The internal combustion engine includes a third blow-by gas passage defined in a fourth wall. The first blow-by gas passage to the third blow-by gas passage connect an oil chamber and an oil separator to each other. The second wall includes a first connecting path. The fourth wall includes a second connecting path. The first connecting path connects the first crank chamber and the second crank chamber. The second connecting path connects the third crank chamber and the fourth crank chamber to each other. The third wall does not have a passage connecting the second crank chamber and the third crank chamber to each other.

Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.

Abstract: An internal combustion engine includes a first blow-by gas passage defined in a second wall. The internal combustion engine includes a second blow-by gas passage defined in a third wall. The internal combustion engine includes a third blow-by gas passage defined in a fourth wall. The first blow-by gas passage to the third blow-by gas passage connect an oil chamber and an oil separator to each other. The second wall includes a first connecting path. The fourth wall includes a second connecting path. The first connecting path connects the first crank chamber and the second crank chamber. The second connecting path connects the third crank chamber and the fourth crank chamber to each other. The third wall does not have a passage connecting the second crank chamber and the third crank chamber to each other.

Abstract: An operation method for a link actuating device provided with a target value input unit having a height direction target value input portion that allows input of a movement amount in a height direction or a coordinate position in the height direction, which causes the distal end posture of the link actuating device to be changed only in the height direction along a central axis of a proximal end side link hub. An input converter is provided to calculate, by using an inputted value, a target distal end posture of the link actuating device. The input converter further calculates a command operation amount of each actuator from the result of the calculation, and inputs the command operation amount to the control device.

Abstract: A diagnostic device is to be used for a link actuation device. A distal end side link hub to be coupled to a proximal end side link hub via three or more link mechanisms such that posture of the distal end side link hub is changeable. Each of the three or more link mechanisms is to be associated with a respective one of actuators. A predetermined action is to be carried out under a predetermined condition by driving each of the actuators. A preload applicator is to cause a preload to be applied to the link actuation device. A torque detector is to detect a drive torque of each of the actuators while a preload is being applied. A determiner is to determine whether or not the torque that is detected by the torque detector lies within a predetermined range. A notifier is to notify the determination result.

Abstract: A peptide derivative represented by Formula (I) or a pharmaceutically acceptable salt thereof: wherein X represents an oxygen atom or NR, Y represents NH2, N(Me)H, SH, OH, or phenyl in which any one of hydrogen atoms is replaced by NH2 or OH, and R represents a hydrogen atom or C1-C3 alkyl, provided that the derivative where X is NH, and Y is NH2, and the derivative where X is NH, and Y is N(Me)H are excluded.

Abstract: A compound represented by formula (1): wherein AA represents a particular amino acid residue or a C1-6 alkyl ester thereof, and when there is a plurality of AAs, each AA may be the same as or different from each other and AAs are bonded to each other via an amide bond; an N-terminal nitrogen atom of (AA)m forms an amide bond together with carbonyl (a); Q represents an unsubstituted phenyl group, or a group represented by formula (Q-1), formula (Qa-2), formula (Qa-3), formula (Qa-4), formula (Qa-5), formula (Qa-6) or formula (Qa-7); R1a and R1b each independently represent a hydrogen atom or a C1-6 alkyl group; and m represents an integer of 1 to 10, or a salt thereof.

Abstract: The present invention provides a compound represented by the formula (1): wherein Xa and Ya are each a single bond or the like, cancer antigen peptide A is an MHC class I-restricted cancer antigen peptide, and R1 is a hydrogen atom; a group represented by the formula (2): wherein Xb and Yb are each a single bond or the like, and cancer antigen peptide B is different from the cancer antigen peptide A and is an MHC class I or II-restricted cancer antigen peptide; a group represented by the formula (3): wherein Xc and Yc are each a single bond or the like, and cancer antigen peptide C is an MHC class II-restricted cancer antigen peptide; or cancer antigen peptide D, wherein the cancer antigen peptide D is an MHC class I or II-restricted cancer antigen peptide containing one cysteine residue, or a salt thereof, for example.

Abstract: The present specification relates to adenine conjugate compounds represented by the formula (1), wherein A, L1, L2, X1, R1, R2, R3, and m are as defined herein, or their pharmaceutically acceptable salts. Compounds of formula (1) have immunostimulating properties and may therefore be useful in therapy, for example as vaccine adjuvants. The present specification also relates to a process for preparing adenine conjugate compounds and pharmaceutically acceptable salts thereof, and to pharmaceutical compositions comprising adenine conjugate compounds and their pharmaceutically acceptable salts.

Abstract: The present invention provides a compound represented by the formula (1): wherein Xa and Ya are each a single bond or the like, cancer antigen peptide A is an MHC class I-restricted cancer antigen peptide, and R1 is a hydrogen atom; a group represented by the formula (2): wherein Xb and Yb are each a single bond or the like, and cancer antigen peptide B is different from the cancer antigen peptide A and is an MHC class I or II-restricted cancer antigen peptide; a group represented by the formula (3): wherein Xc and Yc are each a single bond or the like, and cancer antigen peptide C is an MHC class II-restricted cancer antigen peptide; or cancer antigen peptide D, wherein the cancer antigen peptide D is an MHC class I or II-restricted cancer antigen peptide containing one cysteine residue, or a salt thereof, for example.

Abstract: An exhaust manifold includes a body portion and a flange portion. The body portion includes a first split body having a plurality of semi-cylindrical portions, and a second split body having a plurality of semi-cylindrical portions. The semi-cylindrical portions of the first and second split bodies overlie each other, respectively, and define branch pipes. The exhaust manifold includes a first weld bead and a plurality of second weld beads. The first weld bead welds the semi-cylindrical portions defining one of the branch pipes to each other from an outer surface side. The second weld beads weld an outer peripheral portion of the one of the branch pipes to an edge portion of opening in the flange portion. At least one of the second weld beads partially overlaps the first weld bead. End portions of neighboring second weld beads overlap each other and are separated from the first weld bead.

Abstract: A compound has inhibitory activity on Discoidin Domain Receptor 1. The compound includes a urea derivative represented by the formula below or a pharmaceutically acceptable salt thereof.

Abstract: An operation method for a link actuating device provided with a target value input unit having a height direction target value input portion that allows input of a movement amount in a height direction or a coordinate position in the height direction, which causes the distal end posture of the link actuating device to be changed only in the height direction along a central axis of a proximal end side link hub. An input converter is provided to calculate, by using an inputted value, a target distal end posture of the link actuating device. The input converter further calculates a command operation amount of each actuator from the result of the calculation, and inputs the command operation amount to the control device.

Abstract: An operation device for a link actuating device (51) is provided with a target value input unit (57) having a height direction target value input portion (57z) that allows input of a movement amount in a height direction or a coordinate position in the height direction, which causes the distal end posture of the link actuating device (51) to be changed only in the height direction along a central axis of a proximal end side link hub (12). Input converter (58) is provided to calculate, by using an inputted value, a target distal end posture of the link actuating device (51). The Input converter (58) further calculates a command operation amount of each actuator (53) from the result of the calculation, and inputs the command operation amount to the control device (54).

Abstract: A compound has inhibitory activity on Discoidin Domain Receptor 1. A urea derivative is represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein, R1 is trifluoromethyl, trifluoromethoxy, or pentafluorosulfanyl; each R2 is independently a hydrogen atom or methyl which is optionally substituted by one hydroxyl or one saturated heterocyclyl having four to six ring-forming atoms; R3 is a hydrogen atom, halogen atom, C1-C3 alkyl, saturated heterocyclyl having four to six ring-forming atoms and optionally having an oxo group, or R5O—; and R4 is phenyl, pyridyl, pyridazinyl, or pyrimidinyl, which phenyl, pyridyl, pyridazinyl, or pyrimidinyl is optionally substituted by one R6.

Abstract: An exhaust manifold includes a body portion and a flange portion. The body portion includes a first split body having a plurality of semi-cylindrical portions, and a second split body having a plurality of semi-cylindrical portions. The semi-cylindrical portions of the first and second split bodies overlie each other, respectively, and define branch pipes. The exhaust manifold includes a first weld bead and a plurality of second weld beads. The first weld bead welds the semi-cylindrical portions defining one of the branch pipes to each other from an outer surface side. The second weld beads weld an outer peripheral portion of the one of the branch pipes to an edge portion of opening in the flange portion. At least one of the second weld beads partially overlaps the first weld bead. End portions of neighboring second weld beads overlap each other and are separated from the first weld bead.

Abstract: A peptide derivative represented by Formula (I) or a pharmaceutically acceptable salt thereof: wherein X represents an oxygen atom or NR, Y represents NH2, N(Me)H, SH, OH, or phenyl in which any one of hydrogen atoms is replaced by NH2 or OH, and R represents a hydrogen atom or C1-C3 alkyl, provided that the derivative where X is NH, and Y is NH2, and the derivative where X is NH, and Y is N(Me)H are excluded.

Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.

Abstract: A compound has inhibitory activity on Discoidin Domain Receptor 1. The compound includes a urea derivative represented by the formula below or a pharmaceutically acceptable salt thereof.

Abstract: The present specification relates to adenine conjugate compounds represented by the formula (1), wherein A, L1, L2, X1, R1, R2, R3, and m are as defined herein, or their pharmaceutically acceptable salts. Compounds of formula (1) have immunostimulating properties and may therefore be useful in therapy, for example as vaccine adjuvants. The present specification also relates to a process for preparing adenine conjugate compounds and pharmaceutically acceptable salts thereof, and to pharmaceutical compositions comprising adenine conjugate compounds and their pharmaceutically acceptable salts.